Abnova Presents World’s First, Expanding NanoAb™ Product Catalog to Accelerate Drug Research and Digital RNA Revolution

Abnova Presents World’s First, Expanding NanoAb™ Product Catalog to Accelerate Drug Research and Digital RNA Revolution

Neihu, Taiwan (December 23, 2024)  

Abnova announced the world’s first, expanding NanoAb™ product catalogue to accelerate all facets of drug research and digital RNA revolution.  Abnova’s NanoAb™ is derived from camelid antibodies in contrast to conventional mouse and rabbit antibodies which have supported and facilitated the biotech research and industry in the past 20 years.  While camelid antibody as a service business model has been increasing in recent years, no company has so far dedicated and created a high throughput production platform to generate a plethora of easy-to-access and widely available camelid antibodies. Moreover, the construction and utility of current camelid antibodies are still based on the full-size antibody with Fc domain which severely limits its therapeutic and diagnostic applications and RNA translation.  Abnova has overcome these barriers to develop, manufacture and commercialize a wide spectrum of small size NanoAb™ as fundamental, modular elements to create the next generation of novel classes of antibodies and RNA products.

Abnova’s NanoAb™ composed only of VHH heavy chain (15KDa) is one-tenth the size compared to the conventional antibody with heavy and light chains and Fc domain (150KDa).  Due to the small size, NanoAb™ is efficiently scaled up by many protein expression platforms such as E. coli, mammalian, and cell-free wheat germ systems.  NanoAb™ is more soluble than scFv counterpart of the regular antibody and is highly stable under pH, temperature, and enzymatic stress enabling ease of purification for downstream utilization.  Moreover, NanoAb™ hierarchical ranking of affinity and specificity is higher than mouse and rabbit antibodies.  These unique attributes were first applied as a VHH drug for thrombotic thrombocytopenic purpura and thrombosis blood disorder in 2018 and a lentiviral-based VHH CAR T for multiple myeloma in 2022.  They are also currently evaluated in clinical trials as full-fledge IgG bispecific recombinant antibodies for cancer treatment.  These important milestones signify a new era of VHH antibodies as powerful weapons against the challenges of human diseases and unmet medical needs.

In addition to introducing NanoAb™ as an expanding VHH antibody catalogue product, Abnova aims to create a repertoire of NanoAb™ diversified products in 2025 including conjugated NanoAb™, nanoBiTE™, and nanoTriTE™.  Abnova is the sole manufacturer and provider of these novel products to the worldwide markets through a network of distributors.  More importantly, the short sequence of NanoAb™ VHH can be digitized into mRNA and circRNA molecular backbones thereby establishing new classes of RNA biologics for ex vivo and in situ applications.  This undertaking is not possible with regular long sequence VH+VL domains of traditional antibody.  In essence, NanoAb™ underpins the transformation of analog protein to the digital world of RNA, paving an exciting roadmap for seamless AI integration.

Abnova NanoAb™ product link: https://www.abnova.com/en-global/product?category=AZ0000000000